Abstract: Objective To evaluate the efficacy and safety of atomization inhalation of Tanreqing injection (TRQ) in the treatment of chronic obstructive pulmonary disease (COPD). Methods The databases of CNKI, Wanfang data, VIP, SinoMed, PubMed, Cochrane Library and Web of Science were searched for literature on randomized controlled trials (RCT) of TRQ atomization inhalation in the treatment of COPD that was published between inception and May 22, 2022. The Cochrane Collaboration’s risk of bias evaluation tool was used to evaluate the methodological quality of the included studies. Revman 5.4.1 software was used for statistical analysis of the data, while TSA software developed by Copenhagen Clinical Trial Center was used for trial sequential analysis. Results Aerosol inhalation of TRQ combined with conventional treatments could not only improve the total effective rate of COPD treatment, but more significantly improve PaO2, than conventional treatments alone and budesonide or terbutaline atomized inhalation combined with conventional treatments. Aerosol inhalation of TRQ combined with conventional treatments could reduce inflammatory factor TNF-α more effectively than conventional treatments alone. Only a small number of studies have reported adverse events in the treatment of COPD with aerosol inhalation of TRQ. Conclusion Aerosol inhalation of TRQ is effective for the treatment of COPD to some extent, but the evidence available is not adequate enough to draw conclusions on the safety of this approach. Follow-up studies should be designed and registered in accordance with the internationally recognized SPIRIT Declaration, and standardized clinical trials with sufficient samples should be conducted. More comprehensive indicators should be selected in combination with the guidelines to provide high-quality evidence-based medical evidence for clinical practice.

Key words: Tanreqing injection, aerosol inhalation, chronic obstructive pulmonary disease, Meta analysis